Hyderabad: Bharat Biotech International Limited has announced that it has partnered with GSK plc for the ongoing development and potential use of the Shigella vaccine candidate, ...

Bharat Biotech joins GSK to develop a Shigella vaccine to fight shigellosis in children, with Phase 3 trials underway and ...

First children vaccinated in clinical study seeking to expand the target population for the chikungunya vaccine. COPENHAGEN, Denmark, June 12, 2025 - Bavarian Nordic A/S (OMX: BAVA) announced ...

Two posters presented at the 2025 European Hematology Association Congress support combination therapy with daratumumab, ...

Three of eight evaluable patients with R/R AML responded after cycle 1 in ongoing cohort 8, including 1 patient with ongoing response beyond 6 monthsAcceptable safety profile across all cohorts, inclu ...

Topline data were announced from a phase 3 trial evaluating CTx-1301 for the treatment of pediatric patients aged 6 to 17 years with ADHD.

Tebipenem's approval in 2026 under SPA could bring Spero $400M+ in milestones & royalties. Read more on why SPRO is a Buy, ...

Regulatory action was based on data from the Phase III IMforte trial, which showed that Zepzelca plus Tecentriq significantly ...

Sibeprenlimab clinically reduces proteinuria in adults with immunoglobulin A nephropathy (IgAN), according to data from a prespecified analysis of the phase 3 VISIONARY trial. The findings were ...

Black patients tend to experience more aggressive instances of MS and face greater barriers to diagnosis and treatment.

Late-breaking data reveal durable improvements in joint, skin, and quality of life outcomes with deucravacitinib.

Mezzion Pharma Co., Ltd. (Mezzion) announced a major milestone in their clinical development program, having secured approximately $20 million USD in strategic funding to support the ongoing global ...